18 June 2021
Effective testing for SARS-COV-2 remains a vital part of a national strategy to suppress virus transmission and save lives. Boosting testing through higher and more effective Ag RDT use as part of this strategy is strongly encouraged.
Following the update we sent you on 20 May on scaling up COVID-19 diagnostics using Ag RDTs, we would like to share additional information that WHO has recently circulated to partners and WHO Regional Offices:
We strongly encourage C19RM applicants to consider the above information when developing their C19RM funding requests, in order to optimize access to high quality, cost-effective (US$3 per Ag RDT vs. US$20 per XPert SARS CoV-2 cartridge), and decentralized COVID-19 testing within national responses.
WHO is updating its Ag RDT guidance as well as preparing interim guidance on Recommendations for National SARS-CoV-2 Testing Strategies and Diagnostic Capacities. The new guidance is expected in the coming weeks.